Search results

ANSTO to receive a new grant to continue to fight chronic kidney disease killer in Sri Lanka.

X-ray crystallography at the Australian Synchrotron contributed to major research findings.

The Australian Synchrotron has played a crucial role in the discovery of a new cancer drug for the treatment of leukaemia.

See details of previously published customer updates from our Health products team. 

Using the past to illuminate the future: Brothers collaborate on important science documentary for ABC TV

ANSTO User Meeting 2021 - Speakers

Dr Mathew Johansen, an environmental scientist at ANSTO, presented in an online IAEA training workshop on Advanced Topics in Radiochemistry Techniques this week.

ANSTO has been tracking and publishing data on fine particle pollution from key sites around Australia, and internationally, for more than 20 years.  

In May 2023, The Honourable Dr Annabelle Bennett, ANSTO Board Chair, shared ANSTO's Statement of Intent with the Minister for Industry, Science and Technology.

Planning is now underway for a second repatriation project which is scheduled to take place in 2022. Find out more information.

A special inaugural event held by ANSTO at its Australian Synchrotron for more than 30 funding organisations has showcased the first of the $100 million BRIGHT Program’s brand new, state-of-the-art beamlines.

ANSTO commenced an aerosol sampling program thirty years ago this week to characterise these pollutants and ultimately, identify their sources, which has taken it to the forefront of environmental monitoring of this type in Australia and the region.

The NSW Government will invest $12.5 million to support the expansion of the Innovation Precinct at the Lucas Heights campus of the Australian Nuclear Science and Technology Organisation (ANSTO).

The Think Science! competition encourages students in Years 3-10 to learn science inquiry skills in a fun and accessible way! Entry is FREE and there are generous prizes for winning schools. Any topic can be chosen, and special materials are not required.

Phase contrast tomography shows great promise in early stages of study and is expected to be tested on first patients by 2020.